{
    "Trade/Device Name(s)": [
        "Access NT-proBNP"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K232164",
    "Predicate Device Reference 510(k) Number(s)": [
        "K072437",
        "K201312"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBC"
    ],
    "Summary Letter Date": "April 12, 2024",
    "Summary Letter Received Date": "March 15, 2024",
    "Submission Date": "March 15, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1117"
    ],
    "Regulation Name(s)": [
        "B-Type Natriuretic Peptide Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "NT-proBNP (N-terminal pro B-type natriuretic peptide)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (Lithium Heparin)",
        "Plasma (EDTA)"
    ],
    "Specimen Container(s)": [
        "Lithium Heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "DxI Access Immunoassay Analyzer",
        "DxI 9000 Access Immunoassay Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Paramagnetic particle immunoassay"
    ],
    "Methodologies": [
        "Two-site (sandwich) immunoenzymatic assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Buffer"
    ],
    "Document Summary": "FDA 510(k) summary for Beckman Coulter Access NT-proBNP chemiluminescent immunoassay for quantitative determination of NT-proBNP in serum and plasma.",
    "Indications for Use Summary": "Aids in diagnosis of acute heart failure in emergency department, assessment of heart failure severity, risk stratification of heart failure and acute coronary syndrome patients, using serum or plasma samples on DxI Access Immunoassay Analyzers.",
    "fda_folder": "Clinical Chemistry"
}